Translation of "Développement de produits pharmaceutiques " (French → English) :

4. Asks the Commission and the Member States to provide concrete financial support for pharmaceutical-related transfer of technology and capacity-building for developing countries and local production of pharmaceuticals in all developing countries, especially LDCs, in discharging the obligations established by Article 66.2 of the TRIPS Agreement;

3. The licence shall be strictly limited to all acts necessary for the purposes of production and distribution of a pharmaceutical product and its export to the importing country or countries cited in the application or to a developing or least-developed country party to a regional trade agreement, at least half of the current membership of which is made up of countries presently on the United Nations list of least-developed countries, to the extent necessary to enable a pharmaceutical product produced or imported under a compulsory licence in that country to be exported to t ...[+++]he markets of those other developing or least-developed country parties to the regional trade agreement that share the health problem in question.

– (PT) Our commitment to combating transmissible diseases, with particular focus on poverty-related diseases, such as AIDS, tuberculosis and malaria, and on improving vaccination and healthcare levels by the more developed countries funding health programmes, by removing barriers of access (licences and patents) to pharmaceutical products faced by developing countries and the barriers faced by international partnerships in developing new generations of products is crucial.

Equally important is removing barriers, such as licences and patents, to access by developing countries to pharmaceutical products and international partnerships for developing new generations of products.

Legislative and regulatory instruments are in place in most developed countries to prevent importation, in certain circumstances, of pharmaceutical products, but these instruments risk becoming insufficient where substantial volumes of heavily discounted pharmaceuticals are sold to the poorest developing country markets and the economic interest in trade diversion into high priced markets therefore may increase significantly.

Price segmentation between developed country markets and the poorest developing country markets is necessary to ensure that the poorest developing countries are supplied with essential pharmaceutical products at heavily reduced prices. Therefore, these heavily reduced prices cannot be understood as a reference for the price to be paid for the same products in developed country markets.